Ipamorelin is not currently available at telos rx. There is no intake for it, no way to add it to an existing plan, and no confirmed date for when that might change. Here is exactly what that status means and does not mean.
Ipamorelin is not currently offered by telos rx for compounding. It is under review, not approved, with no confirmed timeline. Telos rx currently offers BPC-157, PT-141, NAD+ nasal spray, and sermorelin for patients who want to start a compounded peptide protocol today.
The short version, stated directly
telos rx does not sell, ship, prescribe, or stock ipamorelin in any form. There is no product page with pricing, no intake questionnaire, and no way for a provider to add it to your plan even if you ask directly. That is the entire current status, stated as plainly as possible.
This is not a temporary glitch or a simple website error to be fixed. It reflects a genuine program decision, made deliberately rather than by accident, and it applies to every patient equally regardless of history or specific request.
You can read more about telos rx's current status on ipamorelin, which will be updated directly if that status ever changes in the future.
What "under review" actually means operationally
telos rx describes ipamorelin as under review, and that phrase has a specific operational meaning. Internally, the program is evaluating sourcing options with partner compounding pharmacies, the current regulatory picture, and the clinical case for offering the peptide responsibly.
None of that ongoing evaluation has a published timeline. It is not scheduled to conclude by a certain quarter, and no internal target date has been made public, because none has been set with any real confidence.
Being under review is meaningfully different from being rejected outright. It is also meaningfully different from being approved for the program. It is a genuinely open, ongoing question with no forced deadline attached to it.
Why this differs from products telos rx does offer
Compare this to a product telos rx does offer, such as sermorelin. Sermorelin has a live page with pricing, a working intake, and providers actively reviewing new patient submissions every day of the week. That contrast is common across the growth hormone secretagogue category described in published research on the topic, where some compounds have far more clinical infrastructure behind them than others.
Ipamorelin has none of that infrastructure at telos rx yet. There is a fundamental difference between a peptide the program has fully built out and one still sitting in an internal evaluation. That gap is the entire story of ipamorelin's current status at telos rx.
It is worth noting this gap can close relatively quickly once regulatory clarity and quality sourcing align. Building an intake and provider workflow is mainly a matter of program execution, not years of additional research. The open question remains regulatory and evidentiary, not operational.
Key takeaway: Ipamorelin has no intake, no pricing, and no plan pathway at telos rx today, and that status has no confirmed end date.
The regulatory backdrop, briefly
Part of what keeps ipamorelin under review is the regulatory backdrop. A federal advisory committee, the Pharmacy Compounding Advisory Committee, issued nonbinding recommendations in 2026 touching on several research peptides, ipamorelin among the substances discussed.
A nonbinding recommendation is advice given to regulators, not a rule with legal force on its own. Federal compounding rules did not change automatically because of that committee meeting, and no pharmacy gained new authority to compound ipamorelin as a direct result.
Formal rulemaking, if it eventually happens, would move through its own separate process on its own timeline. Nothing about that process is fast-tracked, and its eventual outcome is not predetermined.
How to check whether the status has changed
The most reliable way to confirm ipamorelin's current availability at telos rx is to check the ipamorelin page directly. That page reflects the program's live status, not a snapshot from whenever an article happened to be published.
If ipamorelin becomes available, that page would show an active intake and pricing, the same way every currently offered peptide does today. Until it does, treat any other claim about availability with real skepticism.
Do not rely on secondhand claims from social media, forums, or unaffiliated sellers about telos rx's specific offerings. Those sources are not authoritative about what any particular telehealth program actually has in its own catalog.
What this status is not a statement about
telos rx not offering ipamorelin is not a claim that the peptide is dangerous. It is also not a claim that the underlying research is worthless. It is a statement about program readiness and regulatory clarity, nothing broader than that.
It is also not a permanent decision carved in stone. Programs revisit these evaluations as the regulatory landscape and evidence base evolve, though revisiting a question is not the same thing as a predetermined outcome.
Why telos rx does not offer a waitlist for ipamorelin
Some patients ask whether they can join a waitlist or be notified if ipamorelin becomes available. telos rx does not currently maintain that kind of list for peptides under review, largely because the timeline is too uncertain to make a waitlist meaningful.
Instead, the most reliable approach is checking the ipamorelin page directly whenever you have a new question. That page reflects any change in status the moment it happens, rather than depending on an email list that might lag behind.
If a change does happen, it would show up as an active intake and listed pricing on that page, the same pattern every other current telos rx offering follows today without exception.
What patients sometimes misunderstand about "not offered"
A common misunderstanding is treating "not currently offered" as equivalent to "banned" or "illegal to possess." Those are different legal and regulatory categories. Conflating them leads to confusion about what is actually happening here.
telos rx not offering ipamorelin reflects a specific program and sourcing decision made by this particular telehealth service. It says nothing directly about what other entities may or may not be permitted to do with the same substance under different circumstances.
The safest approach, if you are confused about a specific legal question, is to ask a licensed provider directly. Do not rely on assumptions built from how one company's catalog happens to be structured at a given moment.
How this status compares across the wider peptide category
Ipamorelin is not unique in this respect. Several other research peptides sit in the same under-review status at telos rx, for overlapping reasons tied to regulatory clarity and program readiness rather than anything specific to ipamorelin alone.
Patients researching one of these peptides often find the same pattern repeated. There is real scientific interest, an active online market of unregulated sellers, and a telehealth program that has chosen to wait. It would rather delay than offer something it cannot yet stand behind with confidence.
That pattern is not unique to telos rx either. Many careful telehealth programs draw a similar line between peptides with established compounding pathways and those still working through regulatory and evidentiary questions. It is a conservative approach, and it means some patients wait longer than they would prefer for an answer that has not yet arrived.
Which is right for you today
If ipamorelin's current availability is what you needed to know, the answer is clear and unambiguous. Not available today, no timeline, no exceptions made case by case. If you are looking to start a compounded peptide protocol today, telos rx currently offers BPC-157, PT-141, NAD+ nasal spray, and sermorelin.
Sermorelin sits closest to what most ipamorelin researchers are actually looking for, since both are growth hormone secretagogues. Start an intake to have a licensed provider review whether it fits your goals today.
Frequently Asked Questions
Is ipamorelin available at telos rx right now?
No. There is no intake, pricing, or plan pathway for ipamorelin at telos rx currently, and none of that has changed recently. It is under internal review with no confirmed date for when, or whether, that will change in the future.
Can my provider add ipamorelin to my existing plan?
No. Since ipamorelin is not part of the compounding program, no provider at telos rx can add it to an existing plan, regardless of your specific request or history.
Does "under review" mean ipamorelin will be approved soon?
No. Under review means an evaluation is ongoing, with no set timeline or predetermined outcome. It is not the same as an announcement that approval is imminent.
Did a 2026 regulatory review make ipamorelin available?
No. A federal advisory committee issued nonbinding recommendations in 2026 covering several research peptides. That recommendation did not change what pharmacies are currently permitted to compound.
How can I confirm ipamorelin's current status myself?
Check the telos rx ipamorelin page directly, since it reflects the program's live status. Do not rely on social media or forum claims about telos rx's specific offerings.
What should I do if I need something today?
Consider sermorelin, which is currently available through telos rx and addresses a related biological goal through its own receptor pathway. A licensed provider can discuss the differences and help you decide during an intake review.
telos rx is LegitScript-certified. Compounded medications broadly are not FDA-approved, and ipamorelin is additionally not currently offered by telos rx. This article is general information, not medical advice, and does not replace guidance from your own provider.
See the full range of what telos rx offers today, starting with the closest available option. Read about sermorelin.